Table 4.
Number of Patent Applications for Disease-Specific Cell Technologies for Each Technical Field by Applicant's Nationality
| Technical fields | Number of patent applications | Number of granted patents | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US | JP | FR | BE | IT | KR | CA | US | JP | FR | BE | IT | KR | CA | |
| USPTO | ||||||||||||||
| Genetically engineered cell | 49 | 1 | 1 | 1 | 1 | 4 | 15 | 1 | 2 | |||||
| Drug screening | 6 | 7 | 2 | 1 | 4 | 1 | ||||||||
| Patient-derived cells | 6 | 1 | 4 | 1 | ||||||||||
| Diagnosis | 4 | 2 | 2 | 1 | ||||||||||
| JPO | ||||||||||||||
| Genetically engineered cell | 20 | 2 | 7 | 1 | ||||||||||
| Drug screening | 3 | 10 | 2 | 3 | ||||||||||
| Patient-derived cells | 2 | 1 | 1 | |||||||||||
| Diagnosis | 1 | 3 | 2 | |||||||||||
| EPO | ||||||||||||||
| Genetically engineered cell | 11 | 1 | 1 | 7 | 1 | |||||||||
| Drug screening | 2 | 4 | 2 | |||||||||||
| Patient-derived cells | 1 | |||||||||||||
| Diagnosis | ||||||||||||||